

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Surgery*

Manuscript NO: 90679

Title: Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 07916821

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Doctor, Research Associate

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2023-12-19

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-12-21 07:32

Reviewer performed review: 2024-01-02 10:03

Review time: 12 Days and 2 Hours

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	 [] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 E-mail: office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

I read this meta-analysis with interest. In this study, the authors reviewed the clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer. This study is overall well designed, and the results are interesting. Comments: 1. The manuscript requires an editing. Some minor language polishing should be revised. 2. The abstract should be re-written: Background, aim, methods, results, conclusion. 3. The limit of the study should be discussed. 4. Please update and edit the references list. 5 Images should be improved.